This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Lymphoid leukaemia림프성 백혈병 (림프성백혈병)

A. Classification codesICD-10: C91 | C91.0 acute lymphoblastic leukemia (ALL) | C91.1 chronic lymphocytic leukemia (CLL) | C91.3 prolymphocytic leukemia | C91.4 hairy cell leukemia | C91.5 adult T-cell leukemia/lymphoma | C91.6 prolymphocytic leukemia of T-cell type | Special Copayment Reduction V193 (5% copayment, for 5 years from the registration date)
B. SynonymsAcute lymphocytic leukemia (ALL, acute lymphoblastic leukemia), acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), hairy cell leukemia (HCL), adult T-cell leukemia/lymphoma (ATL)
C. Adult onsetNot low — pediatric and adult — ALL occurs in both children (over 75%) and adults, and adult ALL has a poorer prognosis than pediatric ALL; CLL predominates in adults aged 50 and over and is extremely rare in children
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References

1. History

The history of lymphoid leukemia is closely linked to the history of leukemia as a whole. In 1845, John Hughes Bennett and Rudolf Virchow independently described leukemia ("white blood") clinically. In the 1890s, Paul Ehrlich developed blood cell staining methods, laying the foundation for morphologically distinguishing leukemias of lymphocytic and myelocytic origin.

The revolution in the treatment of pediatric ALL began in the late 1940s. In 1948, Sidney Farber first achieved temporary remission in pediatric ALL with the folate antagonist aminopterin. In the 1960s, pioneering researchers such as Emil J. Frei III introduced the concept of combination chemotherapy, opening the possibility of achieving long-term remission. In the 1970s, Donald Pinkel of St. Jude Children's Research Hospital developed a total therapy protocol including cerebrospinal fluid prophylaxis, demonstrating for the first time that pediatric ALL is curable.

In chronic lymphocytic leukemia (CLL), the introduction in 2001 of rituximab, a monoclonal antibody against CD20, changed the treatment paradigm. FDA approval of the BTK inhibitor ibrutinib in 2014 brought revolutionary change to CLL treatment, and with the introduction of venetoclax, CLL entered the era of chemotherapy-free treatment. In adult ALL, approvals of the bispecific antibody blinatumomab in 2014 and inotuzumab ozogamicin in 2017 followed, and in 2021 CAR-T cell therapy (tisagenlecleucel) was approved for ALL in children and young adults.

2. Causes

The causes of lymphoid leukemia differ by type. In ALL (acute lymphocytic leukemia), genetic predisposition is important, and children with Down syndrome (trisomy 21) have a 10–20-fold higher risk of ALL. Hereditary disorders with defects in DNA damage repair, such as Klinefelter syndrome, Fanconi anemia, and Bloom syndrome, also increase the risk. In twin studies, when ALL develops in one identical twin, the risk for the other twin rises to about 20%.

Viral exposure is associated with some lymphoid leukemias. HTLV-1 (human T-cell lymphotropic virus type 1) is a direct cause of adult T-cell leukemia/lymphoma (ATL, C91.5) and occurs endemically in Japan, the Caribbean, and Central Africa. EBV (Epstein-Barr virus) is associated with Burkitt lymphoma and EBV-positive lymphoproliferation. HIV infection increases the risk of lymphoproliferative disorders through immunosuppression. Radiation exposure was associated with increased ALL risk in studies of Hiroshima and Nagasaki atomic bomb survivors. There are also reports that diagnostic radiation exposure of the fetus during pregnancy slightly increases the risk of childhood leukemia.

In CLL, family history and genetic predisposition are more important than radiation or chemical exposure. First-degree relatives of CLL patients have a 5–7-fold higher risk, and monoclonal B-cell lymphocytosis (MBL) is known to be a precursor state of CLL. In Korea, the incidence of CLL is markedly lower than in the West, and its relative rarity in Asians is presumed to result from a combination of environmental and genetic factors.

3. Genetics

Cytogenetic and molecular genetic abnormalities in lymphoid leukemia are central to establishing treatment strategies and predicting prognosis.

Major genomic abnormalities in ALL:

Major genomic abnormalities in CLL: del(13q14) alone (favorable prognosis), del(11q) (ATM deletion, intermediate risk), trisomy 12 (intermediate risk), del(17p) (TP53 deletion, poor prognosis even with ibrutinib or venetoclax treatment). TP53 mutation and unmutated IGHV status are the key markers of high-risk CLL. In pharmacogenomics, the BTK C481S mutation is the main mechanism of ibrutinib resistance.

4. General epidemiology

Lymphoid leukemia is broadly divided into ALL and CLL, which have very different epidemiological characteristics. ALL accounts for about 15–20% of all leukemias but overwhelmingly 75–80% of childhood leukemias. About 60,000 people worldwide are newly diagnosed with ALL each year. The age distribution is bimodal, with high incidence in childhood (peak at 2–5 years) and over age 50.

In Korea, according to National Cancer Center statistics, there are about 700–900 new ALL cases per year, and ALL is the most common malignancy in children. The incidence of adult ALL is about 1.0–1.2 per 100,000 population. CLL is the most common adult leukemia in the West (30% of all leukemias in the West), but in East Asia, including Korea, its incidence is only 1/5–1/10 of that in the West. Korean CLL patients are estimated at about 100–200 per year, which appears to be due to genetic and environmental differences.

Hairy cell leukemia (HCL) is a very rare B-cell neoplasm accounting for about 2% of all lymphoid leukemias and occurs mainly in middle-aged men. Adult T-cell leukemia/lymphoma (ATL) is concentrated in regions with high HTLV-1 prevalence (mainly Kyushu and Okinawa, Japan) and is rare in Korea.

5. Pathophysiology

Pathogenesis of ALL: Acute lymphoblastic leukemia arises from lymphoid precursor cells (B-cell or T-cell precursors), and oncogenic gene fusions (oncofusions) block differentiation and induce unlimited proliferation. For most pediatric B-ALL, a two-hit cooperating mutation model is proposed: an initiating translocation (e.g., ETV6-RUNX1, BCR-ABL1) expands a precursor B-cell clone, and subsequent additional genomic lesions (PAX5, CDKN2A, IKZF1 deletions, etc.) drive full leukemic transformation. In some ETV6-RUNX1-positive pediatric ALL, the initial translocation is known to occur in utero before birth.

In Ph-like ALL, hyperactivation of JAK1/2-STAT5 signaling and ABL1-like kinases promotes cell survival and proliferation. In T-ALL, NOTCH1 mutations (in the cleavage site of the gamma-secretase complex or the PEST domain) persistently maintain NOTCH transcriptional activity.

Pathogenesis of CLL: Characterized by monoclonal proliferation of mature B cells (CD5+/CD19+/CD23+). B-cell receptor (BCR) signaling is central to CLL cell survival, and BTK (Bruton tyrosine kinase) is the key mediator of this signal. BCR stimulation → PI3K/AKT activation → upregulation of NF-κB and BCL-2 → inhibition of apoptosis → accumulation of CLL cells. Contact with and cytokines (IL-4, IL-21, CXCL12) from the bone marrow microenvironment (stromal cells, T cells, macrophages) support CLL cell survival. BCL-2 overexpression is the key mechanism of apoptosis resistance and is the therapeutic target of venetoclax.

6. Symptoms

ALL (acute lymphocytic leukemia) has an abrupt onset, with symptoms progressing rapidly over days to weeks. The main symptoms due to bone marrow failure are fatigue, weakness, and pallor (anemia), fever and infection (neutropenia), and bleeding tendency, petechiae, purpura, and epistaxis (thrombocytopenia). Lymphadenopathy (cervical, axillary, inguinal) from lymph node infiltration and left upper quadrant discomfort and abdominal distension from splenomegaly and hepatomegaly occur. Bone pain and joint pain from bone infiltration are common initial symptoms in pediatric ALL.

Central nervous system involvement is an important finding in ALL, and headache, nausea, visual changes, cranial nerve palsies (ptosis, diplopia), and signs of meningeal irritation may occur. Superior vena cava syndrome (facial swelling, jugular venous distension, dyspnea) may occur due to a mediastinal mass (T-ALL). CLL (chronic lymphocytic leukemia), by contrast, is often discovered incidentally from abnormal blood test findings in an asymptomatic state (70–80%). When symptoms are present, fatigue, night sweats, weight loss, painless lymphadenopathy, and splenomegaly occur.

7. Signs

Signs of ALL: White blood cell counts on complete blood count vary widely (1,000 to several hundred thousand/μL), and lymphoblasts (blasts) are seen on the peripheral blood smear. Pancytopenia is common, and LDH and uric acid are markedly elevated. Bleeding tendency is confirmed on coagulation tests. When leukemic cells are found on cerebrospinal fluid (CSF) examination, the case is classified as CNS involvement.

Signs of CLL: Leukocytosis (10,000 to several hundred thousand/μL), absolute lymphocyte count ≥5,000/μL (mature B cells). Smudge cells (smear cells, Gumprecht cells) on the peripheral blood smear are characteristic. Immunophenotype shows a CD5+/CD19+/CD20 weakly positive/CD23+ pattern. Monoclonal B-cell lymphocytosis (MBL) can be regarded as an early stage. Clinical staging uses the Rai or Binet staging system. Autoimmune complications such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) occur in 20–25% of CLL.

Hairy cell leukemia (HCL) is characterized by splenomegaly and pancytopenia, with hair-like cytoplasmic projections seen on cells in the peripheral blood. Bone marrow aspiration is often impossible (dry tap). The BRAF V600E mutation is the defining marker of HCL.

8. Screening

There is no standard population screening for either ALL or CLL. However, testing for early diagnosis is recommended in the following situations.

Follow-up of groups at high risk for CLL: First-degree relatives of CLL patients are monitored for abnormal findings through complete blood counts at regular health checkups. When monoclonal B-cell lymphocytosis (MBL) is found, progression to CLL is followed with a complete blood count once a year, and high-risk MBL (lymphocytes ≥3,000/μL) requires closer follow-up. Monitoring of acquired BTK mutations is used in patients on ibrutinib for early detection of emerging resistance.

In cancer patients under follow-up after chemotherapy or radiation therapy, immediate referral to a hematologist is necessary when abnormalities in white blood cells or differential, recurrent infections, or unexplained anemia or thrombocytopenia occur. In children with Down syndrome and patients with other DNA damage repair disorders, attention should be paid to early signs of ALL.

9. Diagnosis

Diagnosis of ALL: Bone marrow aspiration and biopsy are essential, and diagnosis is made by integrating blast percentage (≥20%, or peripheral blood blasts if bone marrow aspiration is not possible), immunophenotype, cytogenetics, and molecular genetic testing according to the WHO 2022 classification. Immunophenotype (flow cytometry): B-ALL (TdT+, CD19+, CD10±, CD20±, CD22+) vs T-ALL (TdT+, CD3, CD7, CD2, CD5). Cytogenetics (karyotype + FISH): t(9;22), t(12;21), 11q23 rearrangement, ploidy, abnormal copy number changes. Molecular genetics: BCR-ABL1, ETV6-RUNX1, KMT2A-AFF1 (MLL-AF4), quantitative BCR-ABL1 PCR (treatment response monitoring), NGS panel (identification of Ph-like ALL kinase fusions).

Assessment of CNS status: CNS involvement is classified (CNS1/CNS2/CNS3) by CSF cytology via lumbar puncture (LP) and imaging (brain MRI). Diagnosis of CLL: Absolute B-cell count ≥5,000/μL + specific immunophenotype (CD5+/CD19+/CD23+/CD20 weakly positive/FMC7-/CD79b-) + confirmation of clonality. The Matutes/Moreau scoring system for flow cytometry is used. Bone marrow biopsy is useful for establishing a baseline before starting treatment or for evaluating AIHA/ITP but is not required for the diagnosis of CLL itself. FISH and NGS results (TP53, IGHV mutation status, del(17p), del(11q), 12+) are central to treatment selection and prognosis. Clinical staging uses Rai stages 0–IV and Binet stages A–C.

10. Treatment

Treatment of ALL

Pediatric ALL: A three-phase approach of induction–consolidation–maintenance is the basis. With pediatric protocols (BFM, COG, AALL series), 5-year OS for standard-risk B-ALL exceeds 90%. Induction consists of vincristine, dexamethasone/prednisolone, asparaginase, and an anthracycline. CNS prophylaxis (CNS-directed therapy) is given as intrathecal high-dose methotrexate ± cranial irradiation (now mostly avoided). Treatment intensity is adjusted according to MRD response.

Adult ALL: Pediatric-inspired regimens (DFCI, MRC UKALL series) have shown superior results to standard adult protocols (Hyper-CVAD) in adults aged 40 or younger and are gradually being adopted. Ph+ ALL: Chemotherapy-free regimens combining dasatinib or ponatinib with blinatumomab are emerging as an innovative alternative (4-year OS 85–90%). Hematopoietic stem cell transplantation (allogeneic HSCT) is considered in high-risk groups (Ph+, KMT2A rearrangement, persistent MRD positivity). New agents: Blinatumomab (CD19/CD3 bispecific antibody), inotuzumab ozogamicin (CD22 antibody-drug conjugate), and tisagenlecleucel (CAR-T, B-ALL second line or later) are used for relapsed/refractory ALL.

Treatment of CLL

Observation (watch-and-wait) is the principle for asymptomatic CLL, and treatment begins when an indication for treatment arises (Binet C, or symptomatic Binet B). BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are central to first-line therapy. Fixed-duration combination therapy with a BCL-2 inhibitor + anti-CD20 (venetoclax + obinutuzumab/rituximab) is also a standard option. In CLL with del(17p)/TP53 mutation, BTK inhibitor- or venetoclax-based regimens are superior to chemoimmunotherapy. Chemotherapy-free triple combinations of targeted agents (BTK inhibitor + venetoclax ± anti-CD20) are being studied as a next-generation treatment strategy.

11. Prognosis

Pediatric ALL: With a 5-year overall survival rate above 90%, it has the highest cure rate among childhood cancers. In standard-risk B-ALL (age 1–9 years, initial WBC <50,000/μL, ETV6-RUNX1 or hyperdiploidy), 5-year OS exceeds 95%. Even in high-risk groups (infant ALL, Ph+ ALL, KMT2A rearrangement, hypodiploidy), survival has improved with intensified therapy and SCT.

Adult ALL: The 5-year survival rate is about 40–50%, markedly lower than in children. In Ph+ ALL, combined TKI therapy has improved 5-year OS to 70–80%. Achieving MRD negativity in adult ALL is the key predictor of long-term survival. CLL: In Rai stages 0–II (low risk), median survival is 10 years or more, similar to the general population; in Rai stages III–IV (high risk), median OS was 4–5 years but is improving markedly with the introduction of BTK inhibitors and venetoclax. CLL with del(17p)/TP53 mutation remains a poor-prognosis group but is being converted into a chronic disease manageable with BTK inhibitors. Hairy cell leukemia (HCL) achieves a complete remission rate of over 95% with cladribine monotherapy and has a very favorable prognosis.

12. Prevention

Primary prevention of lymphoid leukemia is mostly not possible, but the following measures help reduce risk. Minimizing radiation exposure: Avoid unnecessary medical radiation and minimize radiological examinations especially during pregnancy. Preventing HTLV-1 transmission: No use of infected transfused blood (screening performed by Korean blood centers), restriction of breastfeeding (preventing vertical transmission through breast milk from HTLV-1-positive mothers), and prevention of sexual transmission through condom use. HTLV-1 serologic screening in regions at risk for ATL may contribute to prevention.

Follow-up of MBL: In patients with incidentally discovered monoclonal B-cell lymphocytosis (MBL), regular follow-up to detect progression to CLL early is important. Immune management: Prevention of infection by intravenous immunoglobulin (IVIG) administration for hypogammaglobulinemia in CLL patients. Pneumococcal and influenza vaccination. In groups at high genetic risk (Down syndrome, DNA repair disorders), early diagnosis and treatment are carried out through regular consultation with pediatric hematologists.


13. References

  1. Kantarjian H, et al. Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring. Am J Hematol. 2025.
  2. Hallek M, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
  3. Schrappe M, et al. Pediatric Acute Lymphoblastic Leukemia. Hematol Oncol Clin North Am. 2020;34(4):743-756.
  4. Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131(4):379-386.
  5. Kantarjian HM, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-847.
  6. Maude SL, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448.
  7. Seoul National University Hospital Health Information. Acute lymphocytic leukemia. [Internet]. 2024.
  8. Asan Medical Center Disease Encyclopedia. Chronic lymphocytic leukemia. [Internet]. 2024.
  9. Korean Society of Hematology. Clinical practice guidelines for lymphoid leukemia. Seoul: Korean Society of Hematology. 2023.
  10. National Cancer Center. Cancer Registration Statistics in Korea, 2022. Ministry of Health and Welfare (MOHW) and National Cancer Center. 2024.